Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VentriPoint DiagnosticsVPTDF -2.20% EV-to-OCF is -13.63 as of Aug. 11, 2026. The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, VentriPoint Diagnostics ranks better than 83.35% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, VentriPoint Diagnostics's Enterprise Value is $15.28 Mil.
VentriPoint Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.12 Mil. Therefore, VentriPoint Diagnostics's EV-to-OCF for today is -13.63.
The historical rank and industry rank for VentriPoint Diagnostics's EV-to-OCF or its related term are showing as below:
VPTDF'
s EV-to-OCF Range Over the Past 10 Years
Min: -19.47 Med: -4.82 Max: -1.4
Current: -13.31
During the past 13 years, the highest EV-to-OCF of VentriPoint Diagnostics was -1.40. The lowest was -19.47. And the median was -4.82.
VPTDF's EV-to-OCF is ranked better than 83.35% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.85
vs VPTDF: -13.31
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
VentriPoint Diagnostics's PE Ratio (TTM) for today is calculated as:
VentriPoint Diagnostics's share price for today is $0.07335.
VentriPoint Diagnostics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.014.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, VentriPoint Diagnostics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VentriPoint Diagnostics EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, VentriPoint Diagnostics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where VentriPoint Diagnostics's EV-to-OCF falls into.
VentriPoint Diagnostics's current Enterprise Value is $15.28 Mil.
VentriPoint Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VentriPoint Diagnostics (VPTDF) has a EV-to-OCF of -13.63 as of Aug. 11, 2026. According to the industry distribution chart, VentriPoint Diagnostics ranks #142 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 16.6%.
Is VentriPoint Diagnostics' EV-to-OCF too high?
VentriPoint Diagnostics' current EV-to-OCF is -13.63. Based on the distribution chart, VentriPoint Diagnostics ranks #142 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers.
How does VentriPoint Diagnostics' EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, VentriPoint Diagnostics ranks #142 out of 853 companies for EV-to-OCF. This places VentriPoint Diagnostics in the top 17% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 7.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.85, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VentriPoint Diagnostics's current EV-to-OCF is -13.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VentriPoint Diagnostics stock overvalued right now?
VentriPoint Diagnostics (VPTDF) has a current EV-to-OCF of -13.63. The current EV-to-OCF is -13.63. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For VentriPoint Diagnostics (VPTDF), the current EV-to-OCF is -13.63 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. Its flagship product, the Ventripoint Medical System (VMS+), transforms standard 2D and 3D echocardiography and MRI images into accurate three-dimensional heart models and volumetric measurements, enabling clinicians to assess disease severity, track progression, evaluate treatment response, and guide surgical and pharmacological decisions. Additionally, the company has developed VMS+ 3D Echo and MRI software that can be installed on any personal workstation to create a 3D model of the heart's chamber. Geographically, its products are sold in Canada and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VPTDF has been successfully added to your 
